https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Allogene_Therapeutics_IncAllogene Therapeutics Inc - Revizia istoricului2026-04-21T02:03:06ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Allogene_Therapeutics_Inc&diff=405871&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Allogene Therapeutics Inc listata cu simbolul US.ALLO ==Descriere companie== Allogene Therapeutics, Inc. (www.allogene.com) is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizin...2024-09-18T13:36:54Z<p>Pagină nouă: Pagina dedicata companiei Allogene Therapeutics Inc listata cu simbolul US.ALLO ==Descriere companie== Allogene Therapeutics, Inc. (www.allogene.com) is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizin...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Allogene Therapeutics Inc listata cu simbolul US.ALLO<br />
<br />
==Descriere companie==<br />
Allogene Therapeutics, Inc. (www.allogene.com) is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715, ALLO-605, ALLO-316, and ALLO-647.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ALLO" /><br />
<br />
==Ultimele stiri despre Allogene Therapeutics Inc (US.ALLO)==<br />
<dynamicpagelist><br />
category=US.ALLO<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ALLO]][[Categorie:Stiri despre companii]]</div>Admin